Experimental therapy of malignant mesothelioma: New perspectives from anti-angiogenic treatments

Alfonso Catalano, Walter Gianni, Antonio Procopio

Research output: Contribution to journalArticlepeer-review


We reviewed the published literature of clinical studies in malignant mesothelioma (MM), including phase II as well as older single-agent and combination chemotherapy trials with more than 15 patients. While response rates exceeding 30% have been achieved with established cytotoxic drugs in MM therapy, novel chemotherapeutic agents and their combinations appear more promising. This applies especially to the anti-metabolites (i.e. pemetrexed) that produced response rates of up to 45% in combination with platinum compounds. Moreover, agents targeting novel proliferative and survival pathways in MM are developed to improve treatment outcomes. Here, we focused on the role of several angiogenic growth factors in MM biology and the data of MM-oriented studies on angiostatic agents tested in a phase I-II trial. It seems likely that no single treatment modality will be effective by itself. Studies that use combinations of the newer agents, including angiostatic drugs, with chemotherapy, should be conducted.

Original languageEnglish
Pages (from-to)101-109
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Issue number2
Publication statusPublished - May 2004


  • Anti-angiogenic agents
  • Mesothelioma
  • Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Experimental therapy of malignant mesothelioma: New perspectives from anti-angiogenic treatments'. Together they form a unique fingerprint.

Cite this